Exploration of Tolerability and Dose Responses for a Yeast-based Probiotic

November 11, 2026 updated by: Tiffany Weir, Colorado State University

The purpose of this study is to evaluate the tolerability and efficacy of a yeast-based dietary supplement on gastrointestinal, mental, and skin health. Yeasts are naturally present on fruits and plants, and are used to bake bread, beer and wine. Some of these yeasts are commonly consumed and may actually benefit your gut health. The supplemental yeast could strengthen the gut lining or help good bacteria in the gut grow better.

In this study, the investigators will look at how two doses of a yeast-based supplement impacts gut health, bowel movement consistency, and mental health. The study will last 17 weeks and consist of 7 clinic visits (1 screening visit and 6 test visits).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study will take place at Colorado State University in Fort Collins, Colorado, USA. It will last approximately 17 weeks. This is a randomized, double-blind 3-arm crossover study with three treatments (placebo and two doses of Pichia kluyveri). The treatments will be taken for 4 weeks in a random order by every participant. Each treatment phase is separated by a 2-week washout. The first visit is a screening visit, where investigators will determine eligibility. Visit 2-7 are test visits where investigators will collect information on height, weight, waist, and hip measurements. Blood pressure will also be measured and the visit will conclude with a venous blood draw. During this visit, participants will also complete questionnaires about gut, mental, and skin health, menopause symptoms, and physical activity. A stool sample and bowel movement and diet records will be completed at home.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Colorado
      • Fort Collins, Colorado, United States, 80521
        • Colorado State University
        • Principal Investigator:
          • Tiffany Weir, PhD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • between 18-75 years old
  • BMI <30 kg/m2
  • mild/moderate gastrointestinal distress

Exclusion Criteria:

  • Have taken antibiotics within two months of enrollment in the study
  • Are currently taking statins, metformin, NSAIDs, and MAO inhibitors or other medications that could interfere with study outcomes, as determined by the study PI
  • Have a current diagnosis of cancer, liver or kidney disease, gastrointestinal diseases (including Celiac, Crohn's, Ulcerative Colitis), and cardiometabolic disorders (cardiovascular disease, diabetes, etc.)
  • Are pregnant or breastfeeding, or actively trying to lose weight
  • Use excessive alcohol
  • Use of supplements containing probiotics at any dose or if you are participating in other studies that may interfere with the bacteria in your gut.
  • Unable or unwilling to consume capsules, provide stool or blood samples, track bowel movements and symptoms, and attend scheduled clinic visits.
  • Have allergies to study treatments or medical supplies (eg. Latex, yeast, cellulose)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo

Placebo - cellulose and hypromellose

Experimental: Pichia kluyveri 9.9 x 10^7

9.9 x 10^7 Pichia kluyveri in microcrystalline cellulose and hypromellose

Experimental: Pichia kluyveri 1 x 10^8

1 x 10^8 Pichia kluyveri in microcrystalline cellulose and hypromellose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Time Frame: 4 weeks

The Gastrointestinal Symptom Rating Scale (GSRS) is a widely used tool for measuring gastrointestinal symptoms across five domains. The GSRS is scored between "No discomfort" and "Very severe discomfort"

4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Systemic inflammation indicated by circulating Tumor Necrosis Factor Alpha
Time Frame: 4 weeks

Tumor necrosis factor alpha, or TNF-a, is an inflammatory cytokine that is implicated in many diseases.

4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

October 31, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

October 5, 2026

First Submitted That Met QC Criteria

October 5, 2026

First Posted (Actual)

October 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 8533

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.